Sells Barostim, an implantable device that sends electrical pulses to treat heart-failure symptoms, to hospitals serving patients with heart failure.
10-K for FY2025, filed Feb 13, 2026
Hospitals buy Barostim devices, and customers pay after delivery.
10-K for FY2025, filed Feb 13, 2026We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent…View ↗
Under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), revenue is recognized when a…View ↗
Our sales and marketing efforts are directed at EPs, HF specialists, interventional and general cardiologists, and vascular surgeons…View ↗
$56.7M
10-K for FY2025, filed Feb 13, 2026
$56.7M ↗
Hospitals buy Barostim directly in the U.S. and Germany; in Austria, Spain and other European countries, sales go through distributors.
10-K for FY2025, filed Feb 13, 2026
No. It lost $53.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$14.2MView ↗
8-K, filed Aug 6, 2026
Total revenue between $58.0 million and $60.0 million;View ↗
8-K, filed Jun 9, 2026
On June 7, 2026, Jared Oasheim, the Chief Financial Officer (“CFO”) of CVRx, Inc. (the “Company”), gave notice of his intention to resign…View ↗
Growing. Revenue grew 4.3x in 4 years, from $13M in FY2021 to $56.7M in FY2025, about 44% a year.
Expanded product labeling
The older report described seeking additional regulatory claims after the BeAT-HF study; the latest says the FDA expanded Barostim's labeling based on that study and describes a separate trial in a broader heart-failure group.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Feb 13, 2026The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial in order to determine if Barostim demonstrates…View ↗
Loading...